Propiomazine   中文名称: 丙酰马嗪

丙吡嗪（0.2 mg/kg，鼻腔治疗，大鼠）的快速吸收伴随着血浆浓度的迅速降低[3]。给予丙吡嗪（25 mg/kg，腹腔注射，攻击后 0 小时和 3 小时）的大鼠可免受 CCl4 引起的肝损伤[4]。在大鼠中，丙吡嗪（0.31–20 mg/kg，静脉注射）会提高血浆催乳素水平[5]。

Absorption, Distribution and Excretion
APPROX HALF OF METABOLITES OF COMMONLY USED PHENOTHIAZINES ARE FOUND IN URINE & REST IN FECES. ULTIMATE SOJOURN OF PHENOTHIAZINE DRUGS IN BODY IS EXCEEDINGLY LONG. 6 MO AFTER DISCONTINUATION OF THESE DRUGS, VARIOUS METABOLITES ARE DETECTABLE IN URINE. /PHENOTHIAZINES/
PHENOTHIAZINE TRANQUILIZERS CROSS PLACENTA RAPIDLY, & THEY HAVE BEEN MEASURED FOR MANY YR IN URINE & TISSUES OF NEONATES OF TREATED MOTHERS, BUT VERY LOW BLOOD LEVELS OF MOTHERS & FETUSES HAVE BEEN MEASURED ONLY RECENTLY... /PHENOTHIAZINES/

---

Metabolism / Metabolites
Unknown, but most likely hepatic as with other phenothiazines.
Unknown, but most likely hepatic as with other phenothiazines.

Toxicity Summary
Propiomazine is an antagonist at types 1, 2, and 4 dopamine receptors, serotonin (5-HT) receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Its main use as a sedative is due to its antihistamine effect.

---

Protein Binding
81%

---

Interactions
...ENHANCES EFFECT OF CNS DEPRESSANTS: HENCE, DOSE OF BARBITURATES GIVEN CONCOMITANTLY SHOULD BE REDUCED 1/2, DOSES OF MEPERIDINE & MORPHINE SHOULD BE REDUCED 1/4 TO 1/2. /HYDROCHLORIDE/
...ENHANCES ACTION OF...ANALGESICS & ANESTHETICS. /HYDROCHLORIDE/
.../REPORTED/ TO PROTECT EXPTL ANIMALS AGAINST HEPATOTOXIC EFFECTS OF CARBON TETRACHLORIDE...
PHYSOSTIGMINE WAS GIVEN TO 17 PT INLABOR PREVIOUSLY GIVEN SCOPOLAMINE ALONE OR MEPERIDINE & PROPIOMAZINE IN COMBINATION, TO ASCERTAIN ITS EFFECT ON REVERSING THE LOSS OF FETAL HEART RATE VARIABILITY. WITH MEPERIDINE & PROPIOMAZINE COMBINATION, REVERSION OCCURRED IN 10 PT.

[1]. Effects of single doses of propiomazine, a phenothiazine hypnotic, on sleep and oxygenation in patients with stable chronic obstructive pulmonary disease. Respiration. 1990;57(4):239-42.

[2]. Thunander Sundbom L, etal. Sedating antihistamines - risk of severe intoxication. Lakartidningen. 2021 Sep 30;118:21037.

[3]. Bioavailability of the sedative propiomazine after nasal administration in rats. International Journal of Pharmaceutics, 1996, 144 (2), 217-224.

[4]. Promethazine protection in carbon tetrachloride liver injury. An electron microscopic study. Arch Pathol. 1969 Jan;87(1):46-51.

[5]. Effect of propiomazine on plasma prolactin in the rat: counteraction by L-dopa. Proc Soc Exp Biol Med. 1985 Apr;178(4):606-9.

Propiomazine is a member of the class of phenothiazines that is 10H-phenothiazine substituted by a 2-(dimethylamino)propyl group at nitrogen atom and a propanoyl group at position 2. It has a role as a phenothiazine antipsychotic drug, a dopaminergic antagonist, a serotonergic antagonist, a muscarinic antagonist, a histamine antagonist and a sedative. It is a member of phenothiazines, an aromatic ketone and a tertiary amino compound. It derives from a hydride of a 10H-phenothiazine.
Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.
Propiomazine is a phenothiazine derivative and atypical antipsychotic agent with sedative, antiemetic and antipsychotic activities. Propiomazine binds to a variety of receptors, including alpha1, dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. Propiomazine exerts its antiemetic and sedative effects through antagonism at histamine H1 receptors; Its antipsychotic effect is attributed to antagonistic activities at dopamine and 5-HT2 receptors.
Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.

---

Drug Indication
Propiomazine is largely used for its antihistamininc sleep inducing effects in treating insomnia.

---

Mechanism of Action
Propiomazine acts as an antagonist of dopamine 1, 2, and 4 receptors, serotonin (5-HT) receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Its main use as a sedative is due to its antihistamine effect.
...ALSO HAS AN ANTIEMETIC ACTION. /HYDROCHLORIDE/

---

Therapeutic Uses
Antipsychotic Agents, Phenothiazine
A SUBSTITUTED PHENOTHIAZINE USED PRIMARILY FOR ITS SEDATIVE PROPERTIES. IT IS INDICATED FOR RELIEF OF RESTLESSNESS & APPREHENSION BEFORE & DURING SURGERY. IT IS ALSO USED AS ADJUNCT TO ANALGESICS FOR APPREHENSION & RESTLESSNESS DURING LABOR. /HYDROCHLORIDE/

---

Drug Warnings
PT SHOULD BE WARNED ABOUT PERFORMING HAZARDOUS TASKS WHILE ON THE DRUG. ITS SAFE USE DURING THE FIRST TRIMESTER OF PREGNANCY HAS NOT BEEN ESTABLISHED. UNTOWARD EFFECTS ARE USUALLY MILD & RESEMBLE THOSE INDUCED BY OTHER SEDATIVE PHENOTHIAZINES. /HYDROCHLORIDE/
SINCE SEVERE CHEMICAL IRRITATION MAY OCCUR WHEN PERIVASCULAR EXTRAVASATION OF SOLN OCCURS, CARE SHOULD BE EXERCISED WHEN IV ROUTE IS EMPLOYED. /HYDROCHLORIDE/

---

Pharmacodynamics
Although propiomazine is a phenothiazine, it is not used as an antipsychotic. It posesses antihistamine effects and is mostly used as a sedative in treating insomnia.

C20H24N2OS

340.483

340.161

362-29-8

4940

Typically exists as solid at room temperature

1.137g/cm3

500.8ºC at 760mmHg

MP: 160-161 °C; CRYSTALS FROM ISOPROPANOL /MALEATE/
MP: 201-206 °C /HYDROCHLORIDE/
MP: 240-242 °C /METHIODIDE/

256.7ºC

4.897

48.85

0

4

5

24

441

0

CCC(C1=CC=C2C(N(C3=CC=CC=C3S2)CC(N(C)C)C)=C1)=O

UVOIBTBFPOZKGP-UHFFFAOYSA-N

InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3

1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。